Henry Dunant Hospital Athens, Greece.
Int J Cardiol. 2013 Sep 30;168(2):922-7. doi: 10.1016/j.ijcard.2012.10.049. Epub 2012 Nov 25.
BACKGROUND/OBJECTIVES: Acute coronary syndromes (ACS) continue to pose a significant medical and socioeconomic burden worldwide. Optimal management strategy aims to improve short and long-term outcome. The present study aims to assess short-term outcome of real-world ACS patients and evaluate the achievement rate of secondary prevention goals.
The TARGET study is an observational study enrolling 418 consecutive ACS patients from 17 centers countrywide (78.0% males, 63.9 ± 12.9 years). After the in-hospital phase, patients were followed for 6 months. In total, 366 patients were included in the prospective phase of the study. At the end of the follow-up, mortality, major adverse cardiovascular events (MACE), prescription pattern of cardiovascular medications, lipid levels, adherence rate to treatment and behavioral recommendations were measured.
The overall mortality was 4.8% and the rate of MACE was 17.5%. At 6 months, a significantly lower proportion of patients received antiplatelet agents and statins as compared to hospital discharge. At the end of the follow-up, 87.7% of patients remained on statin treatment, yet only 18.2% of patients had LDL cholesterol levels less than 70 mg/dL. The adherence pattern to lifestyle and dietary recommendations remained low (66.2% quit smoking, 55.8% and 81.3% followed physical activity and dietary recommendations respectively).
Despite the low rate of mortality and MACE occurrence rate in this countrywide observational study, the attainment rate of secondary prevention goals is relatively poor. Improvement interventions focusing in these gaps of optimal care provision are expected to have a favorable impact on the prognosis of real world ACS patients.
背景/目的:急性冠状动脉综合征(ACS)在全球范围内仍构成重大的医疗和社会经济负担。最佳的管理策略旨在改善短期和长期预后。本研究旨在评估真实世界 ACS 患者的短期预后,并评估二级预防目标的达标率。
TARGET 研究是一项观察性研究,纳入了来自全国 17 个中心的 418 例连续 ACS 患者(78.0%为男性,63.9±12.9 岁)。住院期间完成后,对患者进行了 6 个月的随访。共有 366 例患者纳入了研究的前瞻性阶段。随访结束时,测量了死亡率、主要心血管不良事件(MACE)、心血管药物的处方模式、血脂水平、治疗和行为建议的依从率。
总死亡率为 4.8%,MACE 发生率为 17.5%。6 个月时,与出院时相比,接受抗血小板药物和他汀类药物治疗的患者比例显著降低。随访结束时,87.7%的患者继续接受他汀类药物治疗,但仅有 18.2%的患者 LDL 胆固醇水平低于 70mg/dL。对生活方式和饮食建议的依从模式仍然较低(66.2%戒烟,55.8%和 81.3%分别遵循体力活动和饮食建议)。
尽管本项全国性观察性研究的死亡率和 MACE 发生率较低,但二级预防目标的达标率相对较差。针对这些最佳治疗提供方面的差距进行改进干预预计将对真实世界 ACS 患者的预后产生有利影响。